i4KIDS I i4KIDS-EUROPE’s Post

🏆 Celebrating Innovation in Medicine: 2024 Nobel Prize The Nobel Prize in Medicine stands as an emblem of unparalleled achievement and innovation in healthcare, catalyzing advancements that revolutionize patient care and scientific inquiry. Each year, it recognizes the brightest minds whose work shapes the future of medicine. In 2024, the esteemed award honors Victor Ambros from the University of Massachusetts Medical School and Gary Ruvkun from Harvard Medical School. Their groundbreaking research on microRNAs—tiny molecules crucial for gene regulation—has earned them this prestigious accolade. 🔬 Revolutionary Discoveries! Ambros and Ruvkun unveiled a fundamental principle of gene regulation, demonstrating how microRNAs control protein production by interacting with messenger RNA. This discovery, originating from studies on the simple roundworm C. elegans, has transformed our understanding of cellular processes and disease pathways. 🌍 Implications for Global Health The implications are vast: their work opens new avenues for treating diseases like cancer, diabetes, and genetic disorders. By decoding the machinery of gene regulation, their contributions pave the way for innovative therapeutics and personalized medicine strategies. 💡 Join the Conversation! What are your thoughts on the impact of microRNA research on future healthcare advancements? How do you see such discoveries shaping clinical practices and public health initiatives? Share your insights below! #NobelPrize #Medicine #HealthcareInnovation #MicroRNA #MedicalResearch #FutureOfHealthcare The Nobel Prize Reference: https://lnkd.in/gXsNpp2s https://lnkd.in/gCPC3P-u https://lnkd.in/guW-HyaF https://lnkd.in/gwFp6UqX https://lnkd.in/gPn-axHr https://lnkd.in/gcZ7eRdb

Researchers at the School of Medicine, led by Mete Civelek, PhD, have made significant strides in understanding cardiovascular diseases like atherosclerosis, a leading cause of heart attacks and strokes. By studying the extracellular matrix secreted by smooth muscle cells, they identified genetic factors influencing plaque stability. Analysing proteins from 123 heart donors, they pinpointed 20 genomic locations linked to plaque composition. This research reveals a gene variant predisposing individuals to atherosclerosis and sheds light on protein types affecting cardiovascular risk. These insights could aid in identifying high-risk patients and developing targeted therapies. Notably, the identification of the LTBP1 protein’s role in plaque stability opens avenues for potential therapeutic targets. Published in Arteriosclerosis, Thrombosis, and Vascular Biology, this work was supported by various organisations, highlighting its significance in combating cardiovascular diseases. To learn more about disruptions in the healthcare industry, subscribe to our newsletter at: https://lnkd.in/dmEUSkca

Leveraging patient cell transdifferentiation into induced neurons to enhance diagnostic yield for neurological genetic disorders, Pengfei Liu, PhD, FACMGG joins this month's journal club to present this innovative workflow for rare disease diagnostics using RNA-seq. During the live journal club event, Dr. Liu will cover: 🧬How transcriptome RNA-seq using accessible tissues can fall short in characterizing genes involved in neurological disorders. 💡The streamlining of cell transdifferentiation into a diagnostic RNA-seq workflow. 🥼The increased molecular diagnostic yield by activating neurological disease-associated genes and neuron-specific isoforms with induced neuron RNA-seq. Gain these insights on June 12 by registering today: https://lnkd.in/eeH-XUHJ #ASHG #HumanGenetics

This is a seminal report recently issued by Life Sciences Ontario regarding Ontario’s Readiness for Genomic Medicine. I participated on a panel discussion with Susan Marlin, President and CEO of Clinical Trials Ontario, Dr. Shaqil Kassam, Medical Oncologist, Southlake Regional Health Centre, and Peter J.B. Sabatini, PhD, FCCMG, Laboratory Geneticist, University Health Network. The panel was moderated by Don Husereau, Adjunct Professor of Medicine at the University of Ottawa.  The report captured the major challenges facing Ontario’s preparedness and offered recommendations to better equip the health system to begin widely rolling out publicly funded Comprehensive Genomic Profiling and Whole Genome Tumour Sequencing for every patient’s cancer in the province of Ontario. Ontario has an opportunity to become a leader in the field of oncologic genomic medicine and become an example for the rest of Canada to follow so all Canadians can benefit from this life-saving technology. Please share widely. #LifeScienceOntario #PrecisionMedicine #Biomarkers #PersonalizedMedicine #CCRAN #Oncology #CancerResearch #CancerAwareness #CancerTreatment #ClinicalTrials #CTOConf2024 #OICR

Friday June 21. 11:30-12:30 BST. For anyone interested in epigenetics, this event is being live streamed so wherever you are you can see it. As the event information describes: "In this talk, Biomodal will introduce the 6-base genome (A, T, C, G, 5mC, and 5hmC) delivered by a powerful new technology, duet multiomics solution evoC. The added resolution of duet evoC will enable improved detection of disease associations, identification of novel biomarkers, development of disease classifiers, and monitoring the progression of disease. We will discuss how the 6-base genome can improve the understanding of tumour biology from liquid biopsy." #epigenetics https://lnkd.in/eVk5umAv

This 10x Genomics blog explores groundbreaking research into developmental pathology, focusing on cystic fibrosis and the intricate process of lung development. Cystic fibrosis affects over 100,000 people globally, typically diagnosed by age 2. While scientists have identified key cells involved in the disease, the underlying developmental errors remain unclear. Understanding the cellular origins of the lung, especially during fetal development, could shed light on genetic lung diseases. Researchers in Toronto profiled fetal lung tissue from 10 to 19 gestational weeks, identifying 58 distinct cell types. Comparing these to adult lung cells revealed differences, raising questions about when disease-contributing cells develop during gestation. Using spatial transcriptomics, the team mapped cellular interactions in the developing lung, focusing on CFTR-expressing cells. This approach revealed important cell relationships and pathways that may influence lung disease, with implications for future lung organoid research. Read the full article on Pathology News: https://lnkd.in/erhkMF33 #digitalpathology #pathologynews

Exciting research on the link between gut microbiome and Alzheimer's disease! This study's systems biology framework, integrating machine learning and multi-omics approaches, uncovers molecular relationships between gut microbial metabolites and non-olfactory G-protein-coupled receptors. The findings have potential implications for AD and other complex diseases. Read more about the research here: #ThoughtLeadership #AlzheimersResearch #HealthScience #SystemsBiology

Check out our last preprint which is investigating the consequences of compromised retinoic acid receptor beta (RARβ) signaling on Huntington’s disease symptomatology onset and progression ! Many thanks to #genomeast Damien PLASSARD & Tao YE for their contributions in bioinformatics analyses ! IGBMC These findings are a new step in the understanding of Huntington’s disease symptomatology, thus opening new possibilities in therapeutic approaches !

🎉🎉🎉 New special issue "Identification of Therapeutic Targets in the Pathogenesis of Neurological Diseases" launched online!!! Guest Editor: Joanna Saluk Submission Deadline: December 31, 2024 Expected subtopics include, but are not limited to: - Identification of new therapeutic neuroinflammatory targets. - Common neurodegenerative diseases, their pathological features, and clinical manifestations in the context of potential therapy targets. - Innovative gene, cell and immunotherapies. - Innovative research on the use of precision medicine technologies to adapt to the features of personalized therapy. - Identification of signaling pathways as molecular targets whose modification may lead to inhibiting the progression of neurodegenerative diseases. - Cellular and animal models to investigate the effects of modulating signaling pathways on neurodegenerative disease progression. - Animal models of neurodegenerative diseases useful for validating the effectiveness of potential therapeutic targets and elucidating the mechanisms of action. - Challenges and future directions: identification of challenges and limitations in neurodegeneration targeting therapeutically. Welcome to contribute!!! https://lnkd.in/evr8ZgsU

Gut Microbiome Linked to Alzheimer's Disease Highlights 🔮 Machine learning models predict 1.09 million gut metabolite-GPCR pairs 🔮 Multi-omics analysis identifies Alzheimer’s-related GPCRs and gut metabolites 🔮 Agmatine reduces levels of C3AR and p-tau in patient iPSC-derived neurons 🔮 Phenethylamine reduces p-tau in Alzheimer's patient iPSC-derived neurons Shifts in the magnitude and nature of gut microbial metabolites have been linked to Alzheimer’s disease (AD), but the specific host receptors that detect and respond to these metabolites remain largely unidentified. In this study, a systems biology framework was developed, integrating machine learning and multi-omics approaches, to uncover molecular relationships between gut microbial metabolites and non-olfactory G-protein-coupled receptors (referred to as the "GPCRome"). The analysis involved evaluating 1.09 million metabolite-protein interactions, encompassing 408 human GPCRs and 335 gut microbial metabolites. Through genetics-derived Mendelian randomization and integrative analyses of human brain transcriptomic and proteomic data, orphan GPCRs, such as GPR84, were identified as potential drug targets in AD. Additionally, triacanthine was experimentally shown to activate GPR84. The study further demonstrated that phenethylamine and agmatine significantly reduce tau hyperphosphorylation (p-tau181 and p-tau205) in AD patient-derived induced pluripotent stem cell neurons. This research presents a systems biology framework that, when broadly applied, can uncover the GPCR targets of human gut microbiota in AD and other complex diseases. https://lnkd.in/g7zd8yY4 #microbiome #dementia #braininflammation #inflammation #gutbrainaxis